Daily Digest: Last 24 Hours: Adolescent Brain Risk, Harm Reduction Gaps, and the Policy Patchwork — February 26, 2026
February 26, 2026 — 20 articles reviewed
This cycle was dominated by converging coverage of adolescent cannabis exposure and psychiatric risk, with multiple articles reinforcing the neurobiological case for delaying initiation. Alongside that clinical signal, a mix of state-level legislative developments and harm reduction stories highlighted how unevenly policy is keeping pace with both the science and the market.
The throughline this cycle is unmistakable: the science on adolescent risk is strong and getting stronger, but policy, market design, and public education are still playing catch-up in ways that leave real patients exposed. Clinicians cannot wait for perfect legislation to have honest, nuanced conversations about who benefits from cannabis, who faces elevated risk, and why the details of dose, age, and product type matter more than ever.
Digest-Level Clinical Commentary
Clinical Reflection
The convergence of recent coverage on adolescent cannabis exposure and psychiatric risk reinforces what our clinical literature increasingly demonstrates: developmental neurotoxicity remains one of the most robust adverse signals in cannabis medicine, particularly regarding psychotic spectrum disorders and cognitive outcomes in users under 25. As practitioners, we must integrate this evidence into our risk stratification conversations while acknowledging that state-level policy evolution continues to outpace our ability to implement evidence-based age-gating and clinical monitoring protocols in real-world settings. These signals collectively argue for more structured clinical frameworks that distinguish between adult therapeutic applications and the genuine developmental vulnerabilities that should constrain pediatric and adolescent access.
Clinical Perspective
Recent coverage highlights an important clinical concern regarding adolescent cannabis use and psychiatric risk, reflecting growing evidence that early exposure may affect neurodevelopmental trajectories during a critical period. Concurrent state-level policy developments suggest that clinical findings are beginning to inform legislative approaches, though implementation of evidence-based harm reduction strategies remains variable across jurisdictions. These trends underscore the need for clinicians to maintain awareness of both the neurodevelopmental vulnerabilities in younger populations and the evolving regulatory landscape that may affect patient access and counseling.
Adolescent Health
Mental HealthRegulationHarm ReductionState Policy💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
